These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31771822)

  • 21. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.
    Li M; Li Y; Zhang Y; Wang X; Lin C
    Medicine (Baltimore); 2024 Feb; 103(7):e37212. PubMed ID: 38363923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
    Hyun HK; Cho EJ; Park SY; Hong YM; Kim SS; Kim HY; Heo NY; Park JG; Sinn DH; Kang W; Jeong SW; Song MJ; Park H; Lee D; Lee YS; Cho SB; An CS; Rhee HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Tak WY; Kweon YO; Yoon KT; Cho M; Cheong JY; Park SH; Kim SU;
    Dig Dis Sci; 2021 Jul; 66(7):2427-2438. PubMed ID: 32856240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
    Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
    Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients.
    Shao C; Shao PP; Chen WT; Lin CC; Lin WR; Yeh CT
    Anticancer Res; 2021 Apr; 41(4):2007-2016. PubMed ID: 33813407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
    Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study.
    Huang CF; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    BMJ Open; 2019 May; 9(5):e026703. PubMed ID: 31061041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
    Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
    Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
    Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
    J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
    J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
    Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
    Chen YC; Teng W; Hsieh YC; Chen WT; Jeng WJ; Huang CH; Lin CC; Chen YC; Lin SM; Lin CY; Sheen IS
    J Formos Med Assoc; 2019 Aug; 118(8):1239-1246. PubMed ID: 30581103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
    El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence.
    Celsa C; Stornello C; Giuffrida P; Giacchetto CM; Grova M; Rancatore G; Pitrone C; Di Marco V; Cammà C; Cabibbo G
    Ann Hepatol; 2022 Jan; 27 Suppl 1():100568. PubMed ID: 34699987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.